A new collaboration – the Young Institute Pharmaceutical Manufacturing Consortium – is set to revolutionise pharmaceutical manufacturing with the use of advanced aseptic processing technology.
The collaboration will focus on on sterile injectables and innovative aseptic manufacturing technology to ensure quality, safety and compliance.
The new consortium is made up of Purdue University, Eli Lilly and Company and Merck & Co..
“We’re on the frontier of Pharma 4.0 — autonomous experimentation, advanced robotics, big data, smart factories, AI and machine learning,” said Karen Plaut, Purdue’s executive vice president for research.
“Through this partnership, we will have a global impact in solving complex problems in the pharmaceutical and biopharmaceutical manufacturing ecosystem.”
The consortium will work to enhance pharmaceutical and biopharmaceutical advanced manufacturing by developing disruptive innovative technologies, autonomous systems, and smart
“Addressing pharma manufacturing challenges requires a significant advancement in technology. With an alliance of this calibre, the consortium will explore greater emphasis on both current and future advanced chemistries and accelerate research of innovative discoveries,” said Elizabeth Topp, director of the Young Institute.
The consortium will leverage the organisations’ collaborative research relationship and workforce development programmes, and will look to create systems equipped with automated visual inspection and in-line process and product quality monitoring.
“Being a founding member of the Young Institute means building on the remarkable legacy of next-generation manufacturing,” said Arup Roy, senior vice president, technical services and manufacturing science at Lilly.
“Together, we will transform the industry with advanced aseptic manufacturing technologies, innovative research, and top-notch education and training to bring pharmaceutical sciences into the future with sterile processing standards. Our work honours Bill Young’s visionary spirit to shape the future of manufacturing and make it a core industry competency for a lasting impact on global communities.”
Merck senior vice president of manufacturing, Dave Maraldo, said generative AI, machine learning and quantum computing are the future of the manufacturing process.
“If our collaborative research efforts can use smart technology to accelerate the timeline from research to market, we can reduce costs and bring critical and effective therapies to patients with greater speed,” Maraldo said.
“Harnessing innovation will help create a safe and sustainable future for the industry, and most importantly, allow us to better serve patients.”
In addition to industry, the Young Institute Consortium will be supported by Purdue’s colleges of Engineering, Pharmacy and Science, which will strengthen its ability to establish strategic priorities for training and education, to foster student engagement and to advance expertise in the field.
